Athenen Therapeutics, Inc. — Form D/A
Athenen Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2020-07-31. The offering totals $15.0M, of which $12.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-07-31
- Form: D/A
- Accession: 0001790234-20-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $15.0M
- Amount sold: $12.0M
- Remaining: $3.0M
- Investors: 3
- Date of first sale: 2019-09-19
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-350383
Issuer
- Name: Athenen Therapeutics, Inc.
- CIK: 0001790234
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116
- Phone: 617-778-2580
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Andrew Levin | Director | BOSTON, MA |
| Adam Rosenberg | Director | Wilmington, DE |
| Sari Epstein | Executive Officer | Boston, MA |
| Sarah Reed | Executive Officer | Boston, MA |
| Adam Rosenberg | Executive Officer | Wilmington, DE |
| James Schneider | Executive Officer | Boston, MA |
| Andrew Levin | Executive Officer | BOSTON, MA |
| Joshua Resnick | Director | New York, NY |
| Aaron Bergener | Executive Officer | Boston, MA |
Other filings by this issuer (1)
More